Press Room

News / Jun 22, 2017

Hovione receives B Corp Certification

Hovione became a Certified B Corp at the B Corp Summer Summit 2017, in Cascais, Portugal

B Corporation Certification logo | Hovione

Hovione is the first Chemical/Pharmaceutical Company integrating this innovative community of companies that use the power of business to solve social and environmental problems.

As a Certified B Corporation Hovione wants to contribute to redefine success in business, meeting the highest standards of social and environmental performance, setting its team members for success and personal satisfaction and aspiring to use the power of markets to solve social and environmental problems. Hovione believe that B Corps, and especially those that are family businesses, through the power of their collective voice, are competing to be Best for the World® and through them society will enjoy a more shared and durable prosperity.

To certify as a B Corp, a set of rigorous social and environmental standards must be met. This is achieved through the B Impact Assessment process that requires four principle areas to be assessed: governance model, workers, environment protection and community involvement, including the impact on its suppliers. Hovione's certification process began almost a year ago. During this period B Lab assessed Hovione's policies and procedures in all locations with its operations around the world (Portugal, Ireland, United States and Asia). They concluded that Hovione follows all the appropriate models and can thus be part of this movement.

This is a global movement of people using business as a force for goodTM with a vision that one day all companies compete not only to be the best in the world, but the Best for the World®.

 

Hovione receives B Corp Certification | Hovione
Sofia Burnay, Carolina Serras Pereira, Marcello Palazzi and Diane Villax

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026